Vanillic
acid, an
oxidized form of vanilla, is a flavoring agent with a creamy odor.
Several studies have reported the neuroprotective effects of vanillic
acid, which are predominantly associated with anti-inflammatory and
antioxidative properties. The anti-inflammatory and antioxidative
properties may result from Akt or ERK signaling activation. The activation
of the mammalian target of rapamycin (mTOR), a key downstream target
of Akt and ERK signaling, is a crucial therapeutic target for treating
depression. However, the antidepressant effects of vanillic acid remain
unknown. The present study applied the forced swim test (FST) to investigate
the antidepressant effects of vanillic acid and its association with
Akt, ERK, and mTOR signaling and upstream α-amino-3-hydroxy-5-methyl-4-isoxazolepropionaic
acid receptor (AMPAR) in the prefrontal cortex (PFC) of mice. Vanillic
acid demonstrated antidepressant effects by significantly reducing
behavioral despair in the FST. None of the treatments changed locomotor
activity. Additionally, vanillic acid increased AMPAR throughput,
Akt, and mTOR signaling but not ERK signaling in the PFC. NBQX (an
AMPAR blocker), MK 2206 (an Akt blocker), and rapamycin (an mTOR blocker)
used in pretreatment attenuated the antidepressant effects of vanillic
acid, but SL327 (an ERK inhibitor) did not. The immunochemical results
indicated that the antidepressant effects of vanillic acid depend
on the AMPAR–Akt–mTOR signaling transduction pathway.
Our findings reveal an Akt-dependent, but ERK-independent, the mechanism
underlying the antidepressant effects of vanillic acid, which may
be beneficial for some patients with depression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.